NASDAQ: TLPHTalphera Inc Stock
$0.55+0.03 (+5.77%)
Updated May 8, 2025
TLPH Price
$0.55
Fair Value Price
$0.34
Market Cap
$9.42M
52 Week Low
$0.45
52 Week High
$1.27
P/E
-1.1x
P/B
1.18x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$13.00M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.28
Operating Cash Flow
-$13M
Beta
0.88
Next Earnings
May 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
TLPH Overview
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TLPH's potential to beat the market
- TLPH doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
TLPH
RankedUnranked of 60
RankedUnranked of 60
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.25 | A | |
| $4.50 | A | |
| $7.46 | A |
Be the first to know about important TLPH news, forecast changes, insider trades & much more!
TLPH News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TLPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TLPH ($0.55) is overvalued by 60.68% relative to our estimate of its Fair Value price of $0.34 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TLPH ($0.55) is not significantly undervalued (60.68%) relative to our estimate of its Fair Value price of $0.34 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TLPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TLPH due diligence checks available for Premium users.
Valuation
TLPH fair value
Fair Value of TLPH stock based on Discounted Cash Flow (DCF)
Price
$0.55
Fair Value
$0.34
Overvalued by
60.39%
TLPH ($0.55) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TLPH ($0.55) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TLPH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TLPH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.1x
Industry
15.04x
Market
24.22x
TLPH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.18x
Industry
2.16x
TLPH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TLPH's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.9M
Profit Margin
0%
TLPH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$18.2M
Liabilities
$10.2M
Debt to equity
1.28
TLPH's short-term assets ($9.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TLPH's short-term assets ($9.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TLPH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TLPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.3M
Investing
$0.0
Financing
$0.0
TLPH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TLPH vs Pharmaceutical Stocks
Talphera Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.